Moses Makunje - 27 Feb 2026 Form 4 Insider Report for Nuvation Bio Inc. (NUVB)

Reporting relationship: Title: VP, Finance and principal financial and accounting officer.
Issuer ticker: NUVB
Reported as of: 27 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Mar 2026, 20:03:31 UTC
Prior SEC filing: 04 Mar 2025
Source filing: View source filing
Reporting owner signature: /s/ Stephen Dang, Attorney-in-Fact

Key filing fact

Moses Makunje filed Form 4 for Nuvation Bio Inc. (NUVB) on 03 Mar 2026.

Key facts

This page summarizes Moses Makunje's Form 4 filing for Nuvation Bio Inc. (NUVB).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 03 Mar 2026, 20:03.

Change

Previous filing in this sequence was filed on 04 Mar 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002001938 Primary reporting owner

Makunje Moses

Relationship: Title: VP, Finance and principal financial and accounting officer.
Address: C/O NUVATION BIO INC., 1500 BROADWAY, SUITE 1401, NEW YORK
Signature: /s/ Stephen Dang, Attorney-in-Fact
Signature date: 03 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NUVB transaction

Class A Common Stock

Award

Transaction value: $0
Shares: +50,761
Change %: +292%
Price: $0.000000
Shares after: 68,137
Date: 27 Feb 2026
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NUVB transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +224,439
Change %
Price: $0.000000
Shares after: 224,439
Date: 27 Feb 2026
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 224,439
Exercise price: $5.91
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Represents the grant of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of Class A Common Stock upon settlement. 25% of the shares subject to the RSUs shall vest on the Issuer's quarterly vesting date following each of the first four anniversaries from 2/27/2026, subject to Reporting Person's continuous service on each such vesting date.

Footnote F2

Includes 1,001 shares acquired on May 19, 2025 and 1,100 shares acquired November 19, 2025 under the 2021 Employee Stock Purchase Plan.

Footnote F3

Option vests as to 25% on the one year anniversary of 2/27/26, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date.

SEC remarks

Title: VP, Finance and principal financial and accounting officer.